Bimekizumab
- Generic Name
- Bimekizumab
- Brand Names
- Bimzelx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418205-77-2
- Unique Ingredient Identifier
- 09495UIM6V
- Background
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 ...
- Indication
Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 47
- Registration Number
- NCT05020249
- Locations
- π°π·
Ps0032 20211, Bucheon-si, Korea, Republic of
π°π·Ps0032 20210, Seongnam-si, Korea, Republic of
π°π·Ps0032 20104, Seoul, Korea, Republic of
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 658
- Registration Number
- NCT04901195
- Locations
- πΊπΈ
Hs0005 50105, Saint Louis, Missouri, United States
πΊπΈHs0005 50194, Omaha, Nebraska, United States
πΊπΈHs0005 50140, Birmingham, Alabama, United States
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 41
- Registration Number
- NCT04718896
- Locations
- π΅π±
Ps0020 40334, Wroclaw, Poland
π΅π±Ps0020 40626, Bialystok, Poland
π΅π±Ps0020 40625, Lodz, Poland
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 508
- Registration Number
- NCT04436640
- Locations
- π§π¬
As0014 40005, Sofia, Bulgaria
π―π΅As0014 20031, Sapporo, Japan
π΅π±As0014 40044, Poznan, Poland
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- π³π±
Amphia Hospital, Breda, Netherlands
π³π±Radboudumc, Nijmegen, Netherlands
π³π±MΓ‘xima Medisch Centrum, Veldhoven, Netherlands
A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 71
- Registration Number
- NCT04255862
- Locations
- π©πͺ
Up0068 001, Berlin, Germany
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 505
- Registration Number
- NCT04242446
- Locations
- πΊπΈ
Hs0003 50270, Seattle, Washington, United States
πΊπΈHs0003 50149, San Antonio, Texas, United States
πΊπΈHs0003 50175, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 509
- Registration Number
- NCT04242498
- Locations
- πΊπΈ
Hs0004 50184, Pembroke Pines, Florida, United States
πΊπΈHs0004 50223, Savannah, Georgia, United States
πΊπΈHs0004 50199, Miami, Florida, United States
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 214
- Registration Number
- NCT04109976
- Locations
- π΅π±
Dv0004 40097, Warsaw, Poland
πΊπΈDv0004 50125, Charlotte, North Carolina, United States
πΊπΈDv0004 50024, Boise, Idaho, United States
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 1131
- Registration Number
- NCT04009499
- Locations
- πΊπΈ
Pa0012 50028, Lexington, Kentucky, United States
π·πΊPa0012 20012, Ryazan, Russian Federation
πΊπΈPa0012 50005, Freehold, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.